Jakawi
(Ruxolitinib)
(15 mg)
(56)
(Tablets)
Jakavi (ruxolitinib) 20 mg 56 tab. NOVARTIS Switzerland
Article:
Indications
- Treatment of diseases associated with splenomegaly or symptoms of primary myelofibrosis (also known as chronic idiopathic myelofibrosis) in adult patients, myelofibrosis due to polycythemia vera or myelofibrosis due to essential thrombocythemia.
- 1567ct
-
Commercial name:Jakawi
-
Сhemical name:Ruxolitinib
-
Dosage:15 mg
-
Quantity:56
-
Release form:Tablets
Сьогодні отримав, все супер, рекомендую